U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C11H14N2O4
Molecular Weight 238.2399
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FELBAMATE

SMILES

NC(=O)OCC(COC(N)=O)C1=CC=CC=C1

InChI

InChIKey=WKGXYQFOCVYPAC-UHFFFAOYSA-N
InChI=1S/C11H14N2O4/c12-10(14)16-6-9(7-17-11(13)15)8-4-2-1-3-5-8/h1-5,9H,6-7H2,(H2,12,14)(H2,13,15)

HIDE SMILES / InChI
Molecular Formula C11H14N2O4
Molecular Weight 238.2399
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/cdi/felbamate.html and https://www.ncbi.nlm.nih.gov/pubmed/8383742

Felbamate is an antiepileptic indicated as monotherapy or as an adjunct to other anticonvulsants for the treatment of partial seizures resulting from epilepsy. Receptor-binding studies in vitro indicate that felbamate has weak inhibitory effects on GABA-receptor binding, benzodiazepine receptor binding, and is devoid of activity at the MK-801 receptor binding site of the NMDA receptor-ionophore complex. However, felbamate does interact as an antagonist at the strychnine-insensitive glycine recognition site of the NMDA receptor-ionophore complex. The mechanism by which felbamate exerts its anticonvulsant activity is unknown, but in animal test systems designed to detect anticonvulsant activity, felbamate has properties in common with other marketed anticonvulsants. In vitro receptor binding studies suggest that felbamate may be an antagonist at the strychnine-insensitive glycine-recognition site of the N-methyl-D-aspartate (NMDA) receptor-ionophore complex. Antagonism of the NMDA receptor glycine binding site may block the effects of the excitatory amino acids and suppress seizure activity. Animal studies indicate that felbamate may increase the seizure threshold and may decrease seizure spread. It is also indicated that felbamate has weak inhibitory effects on GABA-receptor binding, benzodiazepine receptor binding. Felbamate should be used only in those patients who respond inadequately to alternative treatments and whose epilepsy is so severe that a substantial risk of aplastic anemia and/or liver failure is deemed acceptable in light of the benefits conferred by its use. Felbatol is the brand name used in the United States for felbamate.

CNS Activity

Originator

Approval Year

1993
138
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2849
Antagonist
2849
 0.52 mM [IC50]
Antagonist
2849
 2.02 mM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
FELBATOL

Approved Use

Not indicated as a first line antiepileptic treatment (see WARNINGS). Recommended for use only in those patients who respond inadequately to alternative treatments and whose epilepsy is so severe that a substantial risk of aplastic anemia and/or liver failure is deemed acceptable in light of the benefits conferred by its use. If these criteria are met and the patient has been fully advised of the risk, and has provided written acknowledgment, Felbamate tablets can be considered for either monotherapy or adjunctive therapy in the treatment of partial seizures, with and without generalization, in adults with epilepsy and as adjunctive therapy in the treatment of partial and generalized seizures associated with Lennox-Gastaut syndrome in children.

Launch Date

1993
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
49 μg/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf027lbl.pdf
45 mg/kg 1 times / day steady-state, oral
dose: 45 mg/kg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
FELBAMATE plasma
Homo sapiens
population: UNKNOWN
age: CHILD
sex: UNKNOWN
food status: UNKNOWN
14.2 μg/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/9241102
1200 mg single, oral
dose: 1200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FELBAMATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
526 μg × h/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/9241102
1200 mg single, oral
dose: 1200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FELBAMATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
20 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf027lbl.pdf
45 mg/kg 1 times / day steady-state, oral
dose: 45 mg/kg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
FELBAMATE plasma
Homo sapiens
population: UNKNOWN
age: CHILD
sex: UNKNOWN
food status: UNKNOWN
19.2 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/9241102
1200 mg single, oral
dose: 1200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FELBAMATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1200 mg 3 times / day steady, oral
Highest studied dose
Dose: 1200 mg, 3 times / day
Route: oral
Route: steady
Dose: 1200 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9579889/
unhealthy, 30 years (range: 18-45 years)
Health Status: unhealthy
Age Group: 30 years (range: 18-45 years)
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9579889/
Other AEs: Headache, Nausea...
Other AEs:
Headache (1 patient)
Nausea (5 patients)
Anorexia (3 patients)
Dyspepsia (1 patient)
Insomnia (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/9579889/
1200 mg 3 times / day multiple, oral
Recommended
Dose: 1200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
Other AEs: Fatigue, Weight decrease...
Other AEs:
Fatigue (6.9%)
Weight decrease (3.4%)
Face edema (3.4%)
Insomnia (8.6%)
Headache (6.9%)
Anxiety (5.2%)
Acne (3.4%)
Rash (3.4%)
Dyspepsia (8.6%)
Vomiting (8.6%)
Constipation (6.9%)
Diarrhea (5.2%)
SGPT increased (5.2%)
Hypophosphatemia (3.4%)
Upper respiratory tract infection (8.6%)
Rhinitis (6.9%)
Diplopia (3.4%)
Otitis media (3.4%)
Bleeding intermenstrual (3.4%)
Urinary tract infection (3.4%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
AEs

AEs

AESignificanceDosePopulation
Dyspepsia 1 patient
1200 mg 3 times / day steady, oral
Highest studied dose
Dose: 1200 mg, 3 times / day
Route: oral
Route: steady
Dose: 1200 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9579889/
unhealthy, 30 years (range: 18-45 years)
Health Status: unhealthy
Age Group: 30 years (range: 18-45 years)
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9579889/
Headache 1 patient
1200 mg 3 times / day steady, oral
Highest studied dose
Dose: 1200 mg, 3 times / day
Route: oral
Route: steady
Dose: 1200 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9579889/
unhealthy, 30 years (range: 18-45 years)
Health Status: unhealthy
Age Group: 30 years (range: 18-45 years)
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9579889/
Insomnia 1 patient
1200 mg 3 times / day steady, oral
Highest studied dose
Dose: 1200 mg, 3 times / day
Route: oral
Route: steady
Dose: 1200 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9579889/
unhealthy, 30 years (range: 18-45 years)
Health Status: unhealthy
Age Group: 30 years (range: 18-45 years)
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9579889/
Anorexia 3 patients
1200 mg 3 times / day steady, oral
Highest studied dose
Dose: 1200 mg, 3 times / day
Route: oral
Route: steady
Dose: 1200 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9579889/
unhealthy, 30 years (range: 18-45 years)
Health Status: unhealthy
Age Group: 30 years (range: 18-45 years)
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9579889/
Nausea 5 patients
1200 mg 3 times / day steady, oral
Highest studied dose
Dose: 1200 mg, 3 times / day
Route: oral
Route: steady
Dose: 1200 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9579889/
unhealthy, 30 years (range: 18-45 years)
Health Status: unhealthy
Age Group: 30 years (range: 18-45 years)
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9579889/
Acne 3.4%
1200 mg 3 times / day multiple, oral
Recommended
Dose: 1200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
Bleeding intermenstrual 3.4%
1200 mg 3 times / day multiple, oral
Recommended
Dose: 1200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
Diplopia 3.4%
1200 mg 3 times / day multiple, oral
Recommended
Dose: 1200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
Face edema 3.4%
1200 mg 3 times / day multiple, oral
Recommended
Dose: 1200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
Hypophosphatemia 3.4%
1200 mg 3 times / day multiple, oral
Recommended
Dose: 1200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
Otitis media 3.4%
1200 mg 3 times / day multiple, oral
Recommended
Dose: 1200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
Rash 3.4%
1200 mg 3 times / day multiple, oral
Recommended
Dose: 1200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
Urinary tract infection 3.4%
1200 mg 3 times / day multiple, oral
Recommended
Dose: 1200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
Weight decrease 3.4%
1200 mg 3 times / day multiple, oral
Recommended
Dose: 1200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
Anxiety 5.2%
1200 mg 3 times / day multiple, oral
Recommended
Dose: 1200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
Diarrhea 5.2%
1200 mg 3 times / day multiple, oral
Recommended
Dose: 1200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
SGPT increased 5.2%
1200 mg 3 times / day multiple, oral
Recommended
Dose: 1200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
Constipation 6.9%
1200 mg 3 times / day multiple, oral
Recommended
Dose: 1200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
Fatigue 6.9%
1200 mg 3 times / day multiple, oral
Recommended
Dose: 1200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
Headache 6.9%
1200 mg 3 times / day multiple, oral
Recommended
Dose: 1200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
Rhinitis 6.9%
1200 mg 3 times / day multiple, oral
Recommended
Dose: 1200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
Dyspepsia 8.6%
1200 mg 3 times / day multiple, oral
Recommended
Dose: 1200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
Insomnia 8.6%
1200 mg 3 times / day multiple, oral
Recommended
Dose: 1200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
Upper respiratory tract infection 8.6%
1200 mg 3 times / day multiple, oral
Recommended
Dose: 1200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
Vomiting 8.6%
1200 mg 3 times / day multiple, oral
Recommended
Dose: 1200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1946

inducer
1087
inhibitor
2438
inhibitor
2507

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP2C19
2057

CYP1A2
2153

CYP2A6
879

CYP2E1
1060
CYP2E1
729

P-gp
2052
CYP2C19
329
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP3A4
2633
 likely
yes (co-administration study)
Comment: Felbamate reduced mean gestodene AUCO-24h by -42% compared with baseline, while a minor decrease (-13%), which was not assessed to be clinically relevant, was observed in ethinyl estradiol AUCO-24h
Page: 7.0
CYP2A6
911
 no
CYP2C9
2497
 no
CYP2D6
2546
 no
CYP2E1
1146
 slight
CYP1A2
2333
 yes [Inhibition 1 uM]
CYP2C19
2141
 yes [Ki 225 uM]
weak (co-administration study)
Comment: AUCtao of phenytoin (substrate) increased by 30% when given Felbamate (1200 mg/day)
Page: 6.0
CYP2C19
2141
 yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
P-gp
2052
 likely
CYP2E1
729
 yes
CYP3A4
1946
 yes
weak (co-administration study)
Comment: Carbamazepine and phenytoin increased felbamate apparent clearance by 32 to 38% relative to monotherapy
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:4995
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:4995
ChemicalBook
CB6689427
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB6689427
eMolecules
538231
https://www.emolecules.com/cgi-bin/more?vid=538231
MolPort
MolPort-003-666-873
https://www.molport.com/shop/molecule-link/MolPort-003-666-873
Selleck Chemicals
Felbamate
http://www.selleckchem.com/products/Felbamate.html
ZINC
ZINC000001530803
http://zinc15.docking.org/substances/ZINC000001530803
PubMed

PubMed

TitleDatePubMed
Interaction between lamotrigine and felbamate in the maximal electroshock-induced seizures in mice: an isobolographic analysis.
2005-03
[West syndrome--new therapeutic approach].
2005-01-11
Mechanisms of action of antiepileptic drugs.
2005
Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII).
2004-12-02
Investigating the role of 2-phenylpropenal in felbamate-induced idiosyncratic drug reactions.
2004-12
Influence of felbamate on selected central effects of ethanol in experimental animals.
2004-10-16
Significance of MDR1 and multiple drug resistance in refractory human epileptic brain.
2004-10-09
Isobolographic and subthreshold analysis of interactions among felbamate and four conventional antiepileptic drugs in pentylenetetrazole-induced seizures in mice.
2004-10
Efficacy and tolerability of the new antiepileptic drugs: comparison of two recent guidelines.
2004-10
Preclinical profile of combinations of some second-generation antiepileptic drugs: an isobolographic analysis.
2004-08
Pharmacodynamic interaction studies with topiramate in the pentylenetetrazol and maximal electroshock seizure models.
2004-07
[Treatment protocol for long-term anti-epilepsy drugs in adults with refractory partial epilepsy].
2004-06
Effect of felbamate and its combinations with conventional antiepileptics in amygdala-kindled rats.
2004-05
New antiepileptic agents.
2004-04-15
Adverse effects of new antiepileptic drugs.
2004-04
Rapid and simple high-performance liquid chromatographic determination of felbamate in serum.
2004-03-10
[Drug interactions with antiepileptic agents].
2004-02-28
A new linker for glucuronylated anticancer prodrugs.
2004-02-15
The new antiepileptic drugs: scientific review.
2004-02-04
Use-dependent inhibition of the N-methyl-D-aspartate currents by felbamate: a gating modifier with selective binding to the desensitized channels.
2004-02
Influence of carbenoxolone on the anticonvulsant efficacy of conventional antiepileptic drugs against audiogenic seizures in DBA/2 mice.
2004-01-19
Effects of seven clinically important antiepileptic drugs on inhibitory glycine receptor currents in hippocampal neurons.
2004-01
Behavioural effects of the newer antiepileptic drugs: an update.
2004-01
Therapeutic drug monitoring of old and newer anti-epileptic drugs.
2004
Pharmacologic treatment of the catastrophic epilepsies.
2004
Treatment of partial seizures in childhood : an overview.
2004
Epilepsy and adolescents.
2003-12
Brain access and anticonvulsant efficacy of carbamazepine, lamotrigine, and felbamate in ABCC2/MRP2-deficient TR- rats.
2003-12
Effects of antiepileptic drugs on refractory seizures in the intact immature corticohippocampal formation in vitro.
2003-11
Infantile spasms.
2003-11
Influence of felbamate on the antinociceptive action of morphine, metamizol and indomethacin in mice.
2003-10-15
Relationship between extent of inhibition and inhibitor dose: literature evaluation based on the metabolism and transport drug interaction database.
2003-10
Is the interaction between felbamate and valproate against seizures induced by 4-aminopyridine and pentylenetetrazole in mice beneficial?
2003-08
Therapeutic drug monitoring of the newer antiepileptic drugs.
2003-06
In vivo CYP3A4 heteroactivation is a possible mechanism for the drug interaction between felbamate and carbamazepine.
2003-06
The ideal pharmacokinetic properties of an antiepileptic drug: how close does levetiracetam come?
2003-05
Interactions of tiagabine with some antiepileptics in the maximal electroshock in mice.
2003-05
Synergistic interaction between felbamate and lamotrigine against seizures induced by 4-aminopyridine and pentylenetetrazole in mice.
2003-03-28
[New epileptic treatments. Current modalities and their utilization].
2003-03-08
Influence of some convulsant agents on the protective activity of a novel antiepileptic drug, felbamate, against maximal electroshock in mice.
2003-03-03
Is there any future for felbamate treatment?
2003-01-05
Effect of antiepileptic drugs on bodyweight: overview and clinical implications for the treatment of epilepsy.
2003
Treatment of Lennox-Gastaut syndrome.
2003
Clinical care of pregnant women with epilepsy: neural tube defects and folic acid supplementation.
2003
Selection criteria for the clinical use of the newer antiepileptic drugs.
2003
Pharmacogenetics--the horizon.
2003
New antiepileptic drug therapies.
2002-11
New antiepileptic drugs.
2002-03
Anticonvulsant drug hypersensitivity.
2002
Effects of anticonvulsant drugs on 4-aminopyridine-induced seizures in mice.
1992-03
Patents

Patents

JP2007512339A
43
JP2007525670A
150
JP4813359B2
3
JPH07309860A
1
JPH0769949A
1

Sample Use Guides

In Vivo Use Guide
Adjunctive therapy: 1200 mg/day in 3-4 divided doses. The daily dose can be increased in 1200 mg increments each week as tolerated to response. Maximum daily dose: 3600 mg. Monotherapy: 1200 mg/day in 3-4 divided doses. Increase the daily dose in 600 mg increments every two weeks as tolerated to response.
Route of Administration: Oral
In Vitro Use Guide
At concentrations of 30 to 100 nM, Felbamate produced a significant inhibition of high-voltage-activated Ca++ currents (-6/-15%). At saturating concentrations (1-3 uM), Felbamate-mediated inhibition averaged 44% in rat cortical and neostriatal neurons.
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:52:41 GMT 2025
Edited
by admin
on Mon Mar 31 17:52:41 GMT 2025
Record UNII
X72RBB02N8
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
FELBAMATE
HSDB   INN   MART.   MI   ORANGE BOOK   USAN   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
FELBATOL
Preferred Name English
ADD-03055
Code English
W-554
Code English
FELBAMATE [ORANGE BOOK]
Common Name English
FELBAMATE [USP MONOGRAPH]
Common Name English
Felbamate [WHO-DD]
Common Name English
CARBAMIC ACID 2-PHENYLTRIMETHYLENE ESTER
Common Name English
FELBAMATE [MI]
Common Name English
2-Phenyl-1,3-propanediol dicarbamate
Systematic Name English
FELBAMATE [USP-RS]
Common Name English
2-PHENYL-1,3-PROPANEDIOL 1,3-DICARBAMATE
Common Name English
felbamate [INN]
Common Name English
1,3-PROPANEDIOL, 2-PHENYL-, DICARBAMATE
Systematic Name English
FELBAMATE [VANDF]
Common Name English
FELBAMATE [USAN]
Common Name English
FELBAMATE [MART.]
Common Name English
TALOXA
Brand Name English
FELBAMATE [HSDB]
Common Name English
NSC-759866
Code English
Classification Tree Code System Code
LIVERTOX NBK548256
Created by admin on Mon Mar 31 17:52:41 GMT 2025 , Edited by admin on Mon Mar 31 17:52:41 GMT 2025
NCI_THESAURUS C264
Created by admin on Mon Mar 31 17:52:41 GMT 2025 , Edited by admin on Mon Mar 31 17:52:41 GMT 2025
NDF-RT N0000008486
Created by admin on Mon Mar 31 17:52:41 GMT 2025 , Edited by admin on Mon Mar 31 17:52:41 GMT 2025
NDF-RT N0000175753
Created by admin on Mon Mar 31 17:52:41 GMT 2025 , Edited by admin on Mon Mar 31 17:52:41 GMT 2025
FDA ORPHAN DRUG 33488
Created by admin on Mon Mar 31 17:52:41 GMT 2025 , Edited by admin on Mon Mar 31 17:52:41 GMT 2025
WHO-ATC N03AX10
Created by admin on Mon Mar 31 17:52:41 GMT 2025 , Edited by admin on Mon Mar 31 17:52:41 GMT 2025
WHO-VATC QN03AX10
Created by admin on Mon Mar 31 17:52:41 GMT 2025 , Edited by admin on Mon Mar 31 17:52:41 GMT 2025
Code System Code Type Description
RS_ITEM_NUM
1269312
Created by admin on Mon Mar 31 17:52:41 GMT 2025 , Edited by admin on Mon Mar 31 17:52:41 GMT 2025
PRIMARY
SMS_ID
100000081237
Created by admin on Mon Mar 31 17:52:41 GMT 2025 , Edited by admin on Mon Mar 31 17:52:41 GMT 2025
PRIMARY
RXCUI
24812
Created by admin on Mon Mar 31 17:52:41 GMT 2025 , Edited by admin on Mon Mar 31 17:52:41 GMT 2025
PRIMARY RxNorm
MESH
C047360
Created by admin on Mon Mar 31 17:52:41 GMT 2025 , Edited by admin on Mon Mar 31 17:52:41 GMT 2025
PRIMARY
NCI_THESAURUS
C47530
Created by admin on Mon Mar 31 17:52:41 GMT 2025 , Edited by admin on Mon Mar 31 17:52:41 GMT 2025
PRIMARY
EPA CompTox
DTXSID9023041
Created by admin on Mon Mar 31 17:52:41 GMT 2025 , Edited by admin on Mon Mar 31 17:52:41 GMT 2025
PRIMARY
IUPHAR
5473
Created by admin on Mon Mar 31 17:52:41 GMT 2025 , Edited by admin on Mon Mar 31 17:52:41 GMT 2025
PRIMARY
EVMPD
SUB07526MIG
Created by admin on Mon Mar 31 17:52:41 GMT 2025 , Edited by admin on Mon Mar 31 17:52:41 GMT 2025
PRIMARY
CAS
25451-15-4
Created by admin on Mon Mar 31 17:52:41 GMT 2025 , Edited by admin on Mon Mar 31 17:52:41 GMT 2025
PRIMARY
HSDB
7525
Created by admin on Mon Mar 31 17:52:41 GMT 2025 , Edited by admin on Mon Mar 31 17:52:41 GMT 2025
PRIMARY
FDA UNII
X72RBB02N8
Created by admin on Mon Mar 31 17:52:41 GMT 2025 , Edited by admin on Mon Mar 31 17:52:41 GMT 2025
PRIMARY
DAILYMED
X72RBB02N8
Created by admin on Mon Mar 31 17:52:41 GMT 2025 , Edited by admin on Mon Mar 31 17:52:41 GMT 2025
PRIMARY
WIKIPEDIA
FELBAMATE
Created by admin on Mon Mar 31 17:52:41 GMT 2025 , Edited by admin on Mon Mar 31 17:52:41 GMT 2025
PRIMARY
DRUG BANK
DB00949
Created by admin on Mon Mar 31 17:52:41 GMT 2025 , Edited by admin on Mon Mar 31 17:52:41 GMT 2025
PRIMARY
USAN
W-17
Created by admin on Mon Mar 31 17:52:41 GMT 2025 , Edited by admin on Mon Mar 31 17:52:41 GMT 2025
PRIMARY
CHEBI
4995
Created by admin on Mon Mar 31 17:52:41 GMT 2025 , Edited by admin on Mon Mar 31 17:52:41 GMT 2025
PRIMARY
MERCK INDEX
m5254
Created by admin on Mon Mar 31 17:52:41 GMT 2025 , Edited by admin on Mon Mar 31 17:52:41 GMT 2025
PRIMARY Merck Index
LACTMED
Felbamate
Created by admin on Mon Mar 31 17:52:41 GMT 2025 , Edited by admin on Mon Mar 31 17:52:41 GMT 2025
PRIMARY
PUBCHEM
3331
Created by admin on Mon Mar 31 17:52:41 GMT 2025 , Edited by admin on Mon Mar 31 17:52:41 GMT 2025
PRIMARY
INN
5686
Created by admin on Mon Mar 31 17:52:41 GMT 2025 , Edited by admin on Mon Mar 31 17:52:41 GMT 2025
PRIMARY
DRUG CENTRAL
1140
Created by admin on Mon Mar 31 17:52:41 GMT 2025 , Edited by admin on Mon Mar 31 17:52:41 GMT 2025
PRIMARY
ECHA (EC/EINECS)
247-001-4
Created by admin on Mon Mar 31 17:52:41 GMT 2025 , Edited by admin on Mon Mar 31 17:52:41 GMT 2025
PRIMARY
NSC
759866
Created by admin on Mon Mar 31 17:52:41 GMT 2025 , Edited by admin on Mon Mar 31 17:52:41 GMT 2025
PRIMARY
ChEMBL
CHEMBL1094
Created by admin on Mon Mar 31 17:52:41 GMT 2025 , Edited by admin on Mon Mar 31 17:52:41 GMT 2025
PRIMARY
Related Record Type Details
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
Structure of FELBAMATE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
Related Record Type Details
Structure of CMBA DERIVATIVE
METABOLITE -> PARENT
Structure of 3-CARBAMOYL-2-PHENYL-PROPIONIC ACID
METABOLITE -> PARENT
Structure of 3-CARBAMOYL-2-PHENYL-PROPIONALDEHYDE
METABOLITE -> PARENT
Related Record Type Details
Structure of N-AMINOCARBONYL FELBAMATE
IMPURITY -> PARENT
Relative Response Factor 0.89
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of 3-HYDROXY-2-PHENYLPROPYL CARBAMATE
IMPURITY -> PARENT
Relative Response Factor 1.3
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of PHENYLPROPANEDIOL
IMPURITY -> PARENT
Relative Response Factor 1.7
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of PHENETHYL CARBAMATE
IMPURITY -> PARENT
Relative Response Factor 1.29
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
Structure of FELBAMATE
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966